New drug aims to unblock Crohn's-Damaged intestines

NCT ID NCT06997965

Recruiting now Disease control Sponsor: Alimentiv Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests whether mirikizumab, an injected drug that blocks IL-23, can reduce inflammatory strictures (narrowed areas) in the small bowel caused by Crohn's disease. About 60 adults with at least one stricture will receive the drug and be monitored with MRI and symptom scores. The goal is to see if the strictures shrink and symptoms improve.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mirikizumab (Omvoh)
What this could lead to: If successful, this could show that mirikizumab helps shrink inflammatory strictures in Crohn's disease, potentially reducing the need for surgery.
What could go wrong: This is a small, early-phase, open-label study with no placebo group, so results may be less reliable. It is not designed to prove a cure, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE

Contacts and locations

Locations

Digestive & Liver Center of Florida
RECRUITING

Orlando, Florida, 32825, United States
GI Institute Research Foundation
RECRUITING

Vancouver, British Columbia, V6Z 2K5, Canada
London Digestive Disease Institute
ACTIVE_NOT_RECRUITING

London, Ontario, N6K1M6, Canada
The Office of Dr. Jason Reinglas
RECRUITING

Scarborough Village, Ontario, M1B 3V4, Canada
Velocity Clinical- Salt Lake City
ACTIVE_NOT_RECRUITING

Salt Lake City, Utah, 84088, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.